Movement Alert｜CSPC PHARMA Rises 3.23% in Regular Trading, Therapeutic mRNA Vaccine Enters Phase II Clinical Trial

Market Focus

07/24

On July 24, CSPC PHARMA rose 3.23% in regular trading, trading at HKD 8.66/share, with turnover of HKD 182 million.

On the news front, the company announced on July 22 that its SYS 6026 injection, a therapeutic mRNA vaccine for treating HPV16 or HPV18-related cervical high-grade squamous intraepithelial lesions, has officially commenced a Phase II clinical trial in China. SYS 6026 is classified as a Category 1 therapeutic biological product, targeting E6 and E7 proteins of HPV16 and HPV18 subtypes. The company had previously received clinical trial approval from China's National Medical Products Administration in November 2024 and has already initiated a Phase I trial evaluating safety and tolerability, with subject recruitment and screening currently underway.

This milestone adds to CSPC PHARMA's recent pipeline momentum, which includes a USD 1.77 billion strategic siRNA collaboration with AstraZeneca announced in early July, a breakthrough therapy designation for SYS6043 in platinum-resistant ovarian cancer, and the Phase II initiation of SYH2070 for mixed hyperlipidaemia.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1170184610"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170184610\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170184610?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170184610","market":"us","top_or_hot":-1,"title":"Movement Alert｜CSPC PHARMA Rises 3.23% in Regular Trading, Therapeutic mRNA Vaccine Enters Phase II Clinical Trial","media":"Market Focus","content":"<p><p>On July 24, CSPC PHARMA rose 3.23% in regular trading, trading at HKD 8.66/share, with turnover of HKD 182 million.</p><p>On the news front, the company announced on July 22 that its SYS 6026 injection, a therapeutic mRNA vaccine for treating HPV16 or HPV18-related cervical high-grade squamous intraepithelial lesions, has officially commenced a Phase II clinical trial in China. SYS 6026 is classified as a Category 1 therapeutic biological product, targeting E6 and E7 proteins of HPV16 and HPV18 subtypes. The company had previously received clinical trial approval from China's National Medical Products Administration in November 2024 and has already initiated a Phase I trial evaluating safety and tolerability, with subject recruitment and screening currently underway.</p><p>This milestone adds to CSPC PHARMA's recent pipeline momentum, which includes a USD 1.77 billion strategic siRNA collaboration with AstraZeneca announced in early July, a breakthrough therapy designation for SYS6043 in platinum-resistant ovarian cancer, and the Phase II initiation of SYH2070 for mixed hyperlipidaemia.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC PHARMA Rises 3.23% in Regular Trading, Therapeutic mRNA Vaccine Enters Phase II Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC PHARMA Rises 3.23% in Regular Trading, Therapeutic mRNA Vaccine Enters Phase II Clinical Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-07-24 09:51</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On July 24, CSPC PHARMA rose 3.23% in regular trading, trading at HKD 8.66/share, with turnover of HKD 182 million.</p><p>On the news front, the company announced on July 22 that its SYS 6026 injection, a therapeutic mRNA vaccine for treating HPV16 or HPV18-related cervical high-grade squamous intraepithelial lesions, has officially commenced a Phase II clinical trial in China. SYS 6026 is classified as a Category 1 therapeutic biological product, targeting E6 and E7 proteins of HPV16 and HPV18 subtypes. The company had previously received clinical trial approval from China's National Medical Products Administration in November 2024 and has already initiated a Phase I trial evaluating safety and tolerability, with subject recruitment and screening currently underway.</p><p>This milestone adds to CSPC PHARMA's recent pipeline momentum, which includes a USD 1.77 billion strategic siRNA collaboration with AstraZeneca announced in early July, a breakthrough therapy designation for SYS6043 in platinum-resistant ovarian cancer, and the Phase II initiation of SYH2070 for mixed hyperlipidaemia.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石藥集團","start_time":0,"source_url":"","article_id":"1170184610","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170184610","pubTimestamp":1784857870,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 24, CSPC PHARMA rose 3.23% in regular trading, trading at HKD 8.66/share, with turnover of HKD 182 million.On the news front, the company announced on July 22 that its SYS 6026 injection, a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"走势预警|石药集团常规交易涨3.23%，治疗性mRNA疫苗进入II期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On July 24, CSPC PHARMA rose 3.23% in regular trading, trading at HKD 8.66/share, with turnover of HKD 182 million.On the news front, the company announced on July 22 that its SYS 6026 injection, a therapeutic mRNA vaccine for treating HPV16 or HPV18-related cervical high-grade squamous intraepithelial lesions, has officially commenced a Phase II clinical trial in China. SYS 6026 is classified as a Category 1 therapeutic biological product, targeting E6 and E7 proteins of HPV16 and HPV18 subtypes. The company had previously received clinical trial approval from China's National Medical Products Administration in November 2024 and has already initiated a Phase I trial evaluating safety and tolerability, with subject recruitment and screening currently underway.This milestone adds to CSPC PHARMA's recent pipeline momentum, which includes a USD 1.77 billion strategic siRNA collaboration with AstraZeneca announced in early July, a breakthrough therapy designation for SYS6043 in platinum-resistant ovarian cancer, and the Phase II initiation of SYH2070 for mixed hyperlipidaemia.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}